SRSF1 and glioblastoma: Analysis of Kaplan–Meier survival curve showed that GBM patients with high immunoexpression of SRSF1 had lower OS times than the GBM group with low immunoexpression of this protein: median OS of patients with high immunoexpression of SRSF1 was 18.0 months (IQR 12.0–23.0), while patients with low SRSF1 levels exhibited median OS of 23.0 months (IQR 18.0–24.0) (p = 0.18).